Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients with chronic kidney disease stage 5 undergoing hemodialysis and receiving paricalcitol iv for more than 1 month.~2. Patients with a RAND 36-Item Health Survey completed 10 to 35 days before paricalcitol iv initiation~3. Patients with baseline parathormone ≥ 300 pg/mL~4. Patients willing to give their informed consent to participate in the study.~5. Patients should not receive vitamin D-related compounds or cinacalcet for 3 months prior to entering the study~6. Patients must be on steady regimen for anemia, hypertension and diabetes for the past 30 days~Exclusion Criteria:~1. Patients with a history of clinically significant intolerance or sensitivity to vitamin D or any ingredients of the product.~2. Patients with persistent hypercalcemia or evidence of vitamin D toxicity.~3. Patients with a continuous increase in serum (calcium x phosphorus) product greater than 65.~4. Pregnant or lactating female patients.~5. Patients who have previously undergone parathyroidectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chronic Kidney Disease, Secondary Hyperpathyroidism (Type: None): All eligible participants treated with paricalcitol iv according to the approved Summary of Product Characteristics (SmPC)

Based on this trial design, predict the completion outcome and termination type (if applicable).